Diflunisal for ATTR cardiac amyloidosis
Congestive Heart Failure, 07/03/2012
Castano A et al. – These data suggest that at low dosages and with careful monitoring, diflunisal can be safely administered to compensated patients with cardiac TTR amyloidosis. Further study in a randomized placebo–controlled trial is warranted.



